These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28711090)

  • 21. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
    Zeidi M; Kim HJ; Werth VP
    J Invest Dermatol; 2019 Feb; 139(2):324-332. PubMed ID: 30227141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chloroquine-quinacrine association in resistant cutaneous lupus.
    Lipsker D; Piette JC; Cacoub P; Godeau P; Frances C
    Dermatology; 1995; 190(3):257-8. PubMed ID: 7599397
    [No Abstract]   [Full Text] [Related]  

  • 24. Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris.
    Akabane AL; Smith GP
    J Am Acad Dermatol; 2021 Oct; 85(4):1046-1047. PubMed ID: 33607179
    [No Abstract]   [Full Text] [Related]  

  • 25. Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study.
    Cesbron E; Bessis D; Jachiet M; Lipsker D; Cordel N; Bouaziz JD; Bagot M; Arnaud L; Barbaud A; Francès C; Chasset F;
    J Am Acad Dermatol; 2018 Jul; 79(1):162-165. PubMed ID: 29496481
    [No Abstract]   [Full Text] [Related]  

  • 26. Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy.
    Chong BF; Werth V
    J Invest Dermatol; 2022 Mar; 142(3 Pt B):936-943. PubMed ID: 34952717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Connective Tissue Disease: Current Concepts.
    Fernandez AP
    Dermatol Clin; 2019 Jan; 37(1):37-48. PubMed ID: 30466687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosacea-like cutaneous lupus erythematosus: an atypical presentation responding to antimalarials.
    Marzano AV; Lazzari R; Polloni I; Boneschi V; Crosti C
    Acta Derm Venereol; 2013 Jan; 93(1):106-7. PubMed ID: 23053047
    [No Abstract]   [Full Text] [Related]  

  • 29. Rhabdomyolysis associated with quinacrine therapy in a patient with chronic cutaneous lupus erythematosus.
    Creel N; Werth V
    J Drugs Dermatol; 2005; 4(2):225-7. PubMed ID: 15776783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.
    Kuhn A; Gensch K; Haust M; Schneider SW; Bonsmann G; Gaebelein-Wissing N; Lehmann P; Wons A; Reitmeir P; Ruland V; Luger TA; Ruzicka T
    J Am Acad Dermatol; 2011 Jul; 65(1):54-64, 64.e1-2. PubMed ID: 21501887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bullous systemic lupus erythematosus: response to dapsone in two patients.
    Sirka CS; Padhi T; Mohanty P; Patel DK; Parida PR; Kar CR
    Indian J Dermatol Venereol Leprol; 2005; 71(1):54-6. PubMed ID: 16394370
    [No Abstract]   [Full Text] [Related]  

  • 32. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
    Chasset F; Francès C; Barete S; Amoura Z; Arnaud L
    J Am Acad Dermatol; 2015 Apr; 72(4):634-9. PubMed ID: 25648824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinacrine: A Treatment Option That Should Not Be Overlooked.
    García-Montero P; Del Boz J; Millán-Cayetano JF; de Troya-Martín M
    Actas Dermosifiliogr; 2016 Dec; 107(10):867-870. PubMed ID: 27523269
    [No Abstract]   [Full Text] [Related]  

  • 34. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.
    Kurtzman DJ; Wright NA; Lin J; Femia AN; Merola JF; Patel M; Vleugels RA
    JAMA Dermatol; 2016 Aug; 152(8):944-5. PubMed ID: 27120749
    [No Abstract]   [Full Text] [Related]  

  • 35. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
    Chasset F; Arnaud L; Jachiet M; Monfort JB; Bouaziz JD; Cordoliani F; Bagot M; Barbaud A; Francès C
    J Am Acad Dermatol; 2018 Jan; 78(1):107-114.e1. PubMed ID: 29061479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dermacase. Dermatomyositis.
    Sowerby L; Turchin I
    Can Fam Physician; 2007 Nov; 53(11):1893, 1902. PubMed ID: 18000263
    [No Abstract]   [Full Text] [Related]  

  • 37. Update on the management of cutaneous lupus erythematosus.
    Callen JP
    Br J Dermatol; 2004 Oct; 151(4):731-6. PubMed ID: 15491411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis.
    Yoshimasu T; Ohtani T; Sakamoto T; Oshima A; Furukawa F
    Eur J Dermatol; 2002; 12(1):50-2. PubMed ID: 11809595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to hydroxychloroquine due to smoking in a patient with lupus erythematosus tumidus.
    Hügel R; Schwarz T; Gläser R
    Br J Dermatol; 2007 Nov; 157(5):1081-3. PubMed ID: 17854374
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
    Zeidi M; Chen KL; Patel J; Desai K; Kim HJ; Chakka S; Lim R; Werth VP
    Lupus; 2022 Apr; 31(4):472-481. PubMed ID: 35258358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.